Product Center
Ab&B Bio-Tech Co., Ltd. has won the Golden Bull Award for 2025 Hong Kong Stock Exchange Listed Companies!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-08
- Views:
(Summary description)On November 8th, the 2025 Outstanding Hong Kong Listed Company Golden Bull Award was announced in Xiamen. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has won the 2025 Growth Value Golden Bull Award for its outstanding achievements and outstanding performance in Hong Kong stock market value.
Ab&B Bio-Tech Co., Ltd. has won the Golden Bull Award for 2025 Hong Kong Stock Exchange Listed Companies!
(Summary description)On November 8th, the 2025 Outstanding Hong Kong Listed Company Golden Bull Award was announced in Xiamen. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has won the 2025 Growth Value Golden Bull Award for its outstanding achievements and outstanding performance in Hong Kong stock market value.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-08 08:59
- Views:
On November 8th, the 2025 Outstanding Hong Kong Listed Company Golden Bull Award was announced in Xiamen. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has won the 2025 Growth Value Golden Bull Award for its outstanding achievements and outstanding performance in Hong Kong stock market value.
The "Listed Company (Hong Kong Stock) Golden Bull Award" hosted by China Securities Journal is a highly credible and authoritative award in the Chinese capital market, aimed at recognizing outstanding Hong Kong listed companies with standardized governance, performance growth, and positive returns to shareholders and society. With a rigorous, scientific, and transparent evaluation system, this award has become one of the most credible professional exchange platforms in China's capital market, effectively promoting the positive interaction between industry and capital.
The "Growth Value Taurus Award" won by the company this time belongs to the "Growth and Innovation Category". The selection process of this award focuses on innovative breakthroughs in cutting-edge technology fields such as artificial intelligence, new energy, and biomedicine. It aims to recognize Hong Kong listed companies that have demonstrated strong comprehensive strength and forward-looking development strategies in high-quality development and industrial transformation. At the same time, it also encourages companies to not only have a fast growth rate, but also to have sustained and stable value creation capabilities.
At the conference, the chairman and general manager of the company, An Youcai, was invited to participate in the roundtable forum on "New Quality Productivity Engine: How AI Reshaps the Value Growth Curve of Hong Kong Listed Companies". We shared the latest developments in our respective fields with numerous industry experts, broke down industry barriers, and conducted cutting-edge thinking collisions and experience exchanges on the application of AI technology and scientific empowerment of the full chain operation of Ab&B Bio's research, production, and sales.
After the meeting, Mr. An accepted an exclusive interview with a reporter from China Securities Journal, focusing on the market performance and future development ideas of Ab&B Bio after its listing on the Hong Kong stock market. He talked about the core logic of Ab&B Bio's highly recognized market after its listing on the Hong Kong stock market, as well as how the company will embrace the wave of change with innovation driven, quality leading, management efficiency improving, and overseas expansion as its strategic axis in the future, and continuously strive towards the vision of enabling China to use global innovative vaccines and the world to use high-quality Chinese vaccines!
Relevant information
-
Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session.On August 5, 2026, a delegation comprising leaders and experts from the Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio-Tech CO.,LTD.JS to conduct an on-site inspection and hold a symposium. During the meeting, both parties engaged in in-depth discussions on topics such as innovative vaccine R&D, clinical evaluation, joint construction of technical platforms, sharing of data resources, talent cultivation, and technology commercialization, thereby accelerating the transition of their strategic cooperation from "paper-based consensus" to "substantive implementation." - The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States. 07-02
- Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
